Results 11 to 20 of about 19,019 (189)
HIV Dynamics and Integrase Inhibitors [PDF]
Antiviral Chemistry and Chemotherapy, 2009 The integrase inhibitor (INI) raltegravir has shown promising results in clinical trials to date, reducing second phase HIV RNA levels by 70% in comparison with standard regimens. These trial results have been limited by the 50 copies/ml detection limit of the HIV RNA assay and have not investigated the effect of an INI regimen on levels of latently ...
John M. Murray
openalex +4 more sources
Pharmacology of HIV integrase inhibitors [PDF]
Current Opinion in HIV and AIDS, 2012 The purpose of this paper is to review recent and relevant pharmacology data for three HIV integrase inhibitors: raltegravir (marketed), dolutegravir and elvitegravir (both in Phase III drug development).
Jessica Adams +2 more
openalex +5 more sources
Biomath, 2012 Antiviral combination therapies consisting of reverse transcriptase inhibitors, protease inhibitors and an integrase inhibitor, have been developed to suppress HIV below the limit of detection.
Dimitra Bon +3 more
doaj +3 more sources
Patterns of resistance development with integrase inhibitors in HIV
Infection and Drug Resistance, 2011 Raltegravir, the only integrase (IN) inhibitor approved for use in HIV therapy, has recently been licensed. Raltegravir inhibits HIV-1 replication by blocking the IN strand transfer reaction. More than 30 mutations have been associated with resistance to raltegravir and other IN strand transfer inhibitors (INSTIs).
P Cane, Jean L. Mbisa, Martín
openalex +5 more sources
HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play? [PDF]
European Journal of Medical Research, 2009 End-stage liver disease has become one of the most frequent causes of death in HIV/HCV-coinfected patients. The role of new antiretrovirals in the progression of liver fibrosis has yet to be defined.
Vogel Martin, Nelson Mark
doaj +2 more sources
Raltegravir: first in class HIV integrase inhibitor
Therapeutics and Clinical Risk Management, 2008 Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Zelalem Temesgen, Dawd S Siraj
doaj +5 more sources
Weight gain and integrase inhibitors [PDF]
Current Opinion in Infectious Diseases, 2020 Purpose of review Weight gain and obesity among people living with HIV (PLWH) is a serious problem that occurs often after initiation of antiretroviral therapy but may be worse with integrase strand transfer inhibitors (INSTIs).
Grace A. McComsey, Allison Ross Eckard
openaire +3 more sources
Resistance to Integrase Inhibitors [PDF]
Viruses, 2010 Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to treatment failure and mutations within the IN coding sequence appear to confer cross-resistance.
Yves Pommier +3 more
openaire +4 more sources
Nature Communications, 2019 Long-acting formulation of the integrase inhibitor cabotegravir (CAB LA) is in clinical development for HIV pre-exposure prophylaxis (PrEP). Here, using a SHIV macaque model, the authors show emergence of integrase mutations associated to CAB LA PrEP ...
Jessica Radzio-Basu +12 more
doaj +1 more source
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes
Retrovirology, 2009 Background Integrase inhibitors are currently being incorporated into highly active antiretroviral therapy (HAART). Due to high HIV variability, integrase inhibitor efficacy must be evaluated against a range of integrase enzymes from different subtypes ...
Kuhl Björn D +7 more
doaj +1 more source